Ludwig Institute for Cancer Research Limited

Maha Ayyoub

Danila Valmori

Benoit Van Den Eynde

Bernard Monsarrat

Jean Edouard Gairin

Honor&eacute; Mazarguil

Honore Mazarguil

The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the SSX-2 gene.

SSX-2 peptides presented by HLA class II molecules

The invention describes HLA class II binding peptides encoded by the SSX-4 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the SSX-4 gene.

SSX-4 peptides presented by HLA class II molecules

The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating to the peptides. The peptides stimulate the activity and proliferation of CD4T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the SSX-2 gene.

Ssx-2 peptides presented by hla class II molecules

Human melanoma cells bear antigens that are recognized by autologous CD8 cytotoxic T-lymphocytes. The invention involves the reception of particular peptides analogues of the MZ2-E antigen by HLA molecules. Disclosed herein are peptide analogues of the tumor antigen MZ2-E that have been modified to resist peptidase degradation, and which bind HLA molecules to form a complex whose recognition by specific cytolytic T cells leads to lysis of the complex. The identification by cytolytic T cells of the peptide analogue/HLA complex may be used in diagnostics, or therapeutically.

Structurally modified peptides that are resistant to peptidase degradation

Human melanoma cells bear antigens that are recognized by autologous CD8+ cytotoxic T-lymphocytes. The invention involves the reception of particular peptides analogues of the MZ2-E antigen by HLA molecules. Disclosed herein are peptide analogues of the tumor antigen MZ2-E that have been modified to resist peptidase degradation, and which bind HLA molecules to form a complex whose recognition by specific cytolytic T cells leads to lysis of the complex. The identification by cytolytic T cells of the peptide analogue/HLA complex may be used in diagnostics, or therapeutically.

Growing community of inventors

New York, NY, United States of America

Maha Ayyoub